Sort
82,697 grants matching “vaccine development”
Exploring mechanisms that govern immune homeostasis in skin
$1,593,687Keisuke Nagao · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors
$1,593,546Alan Thomas Johnson · Hawaii Biotech, Inc. · R01 · FY2015 · AI
Malaria Vaccine: AMA1-C2
$1,593,236Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine
$1,593,039Pyone Aye · Tulane University Of Louisiana · N01 · FY2017 · AI
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
$1,592,871Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Toward a Universal Influenza Virus Vaccine
$1,592,593Peter Palese · Icahn School Of Medicine At Mount Sinai · P01 · FY2013 · AI
Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections Among American Indians/Alaska Natives
$1,592,308Laura Hammitt · Johns Hopkins University · U01 · FY2020 · IP
Manufacturing and Regulatory Support of Ad/MVA and Ad/Protein HIV-1 Vaccines
$1,591,960Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2013 · AI
Pathogenesis of Tick-Borne Flavivirus Infections
$1,591,906Marshall Bloom · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Dynamics and Evolution of Immune Responses to Influenza Viruses
$1,591,719Rustom Noshir Antia · Emory University · U19 · FY2016 · AI
CCR, LGI, Flow Cytometry Core
$1,591,689Ferenc Livak · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Monitoring SIV Reservoirs with Whole Body immunoPET
$1,590,807Francois J Villinger · University Of Louisiana At Lafayette · R01 · FY2017 · AI
Human Papillomavirus (HPV) Natural History, Genomics and Risk Assessment
$1,590,643Mark Schiffman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2016 · CA
B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses
$1,590,568Daved Fremont · Washington University · N01 · FY2019 · AI
Development And Production Of Filovirus DNA Plasmid Vaccines
$1,590,341Kimberly Wallace · Niaid Extramural Activities · Z01 · FY2007 · AI
Production of Alternate Adenovector Filovirus Vaccines
$1,590,341Kimberly Wallace · Niaid Extramural Activities · Z01 · FY2007 · AI
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization
$1,590,054Cynthia Ann Derdeyn · University Of Washington · R01 · FY2025 · AI
Eliciting B cells to produce anti-HIV gp41 MPER-specific neutralizing antibodies
$1,589,966Ellis L Reinherz · Dana-Farber Cancer Inst · U19 · FY2014 · AI
Eliciting B cells to produce anti-HIV gp41 MPER-specific neutralizing antibodies
$1,589,966Ellis L Reinherz · Dana-Farber Cancer Inst · U19 · FY2015 · AI
Comparative Study of Influenza Vaccines in Adults
$1,589,316University Of Michigan At Ann Arbor · U01 · FY2005 · AI
Development of an H2O2-Inactivated Dengue Virus Vaccine
$1,589,072Mark K Slifka · Oregon Health & Science University · R01 · FY2013 · AI
Immune Response Consortium: Integrated In Silico, In Vitro, and In Vivo Studies
$1,588,630Arup K. Chakraborty · Massachusetts Institute Of Technology · P01 · FY2007 · AI
Role of the microbiota in immunity
$1,588,502Yasmine Belkaid · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Vanderbilt HIV Clinical Trials Unit
$1,588,407Richard T D'aquila · Vanderbilt University · U01 · FY2011 · AI
Capturing spatial patterns of new M. tuberculosis infection in Kampala, Uganda
$1,588,271Charles Martyn Bark · Case Western Reserve University · R01 · FY2019 · AI